Ibio Inc (IBIO)
NASDAQ:IBIO
Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$2.06
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.06
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $3.82
Previous CloseN/A
Volume55.53K
Average Volume (3M)961.85K
Market Cap
$84.45M
Enterprise Value-$15.31M
Total Cash (Recent Filing)$74.80M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Sep 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding49,678,562
10 Day Avg. Volume823,376
30 Day Avg. Volume961,852
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap-0.18
Enterprise Value/Revenue-51.02
Enterprise Value/Gross Profit31.89
Enterprise Value/Ebitda0.68
Forecast
1Y Price Target
$5.40Price Target Upside162.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$166.67K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityLow reported debt and a meaningful equity base give iBio structural financial flexibility versus highly leveraged peers. Over the next 2–6 months this reduces interest burden and preserves optionality for financing clinical programs through partnerships or equity without heavy fixed obligations.
Transition To Clinical StageRegulatory clearance to initiate a first-in-human Phase 1 trial marks a durable business inflection: moving from preclinical to clinical materially increases the ability to generate milestone payments, attract partners, and validate biology, improving long-term commercialization prospects.
Board Strength / Management ExperienceAdding an experienced biotech executive with deep clinical development and investment expertise strengthens governance and execution capacity. That durable enhancement supports trial design, regulatory strategy and partner discussions during the multi-quarter path to clinical readouts.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow mean the company consumes cash faster than it generates it, creating structural runway pressure. Over months this necessitates external financing, which can dilute shareholders or disrupt R&D timelines if capital markets are constrained.
Minimal Revenue & Large LossesVery low revenue and deep, persistent losses show the business is not yet commercially self-sustaining. This structural deficiency limits reinvestment capacity, increases reliance on external capital or partnerships, and lengthens the timeline to steady, internally funded growth.
Dependence On External Funding / Dilution RiskHistorical equity swings and the firm’s negative cash generation imply recurring capital raises are likely. Reliance on external financing creates durable dilution and execution risk, potentially constraining long-term strategic choices and making program continuity sensitive to fundraising conditions.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $84.45M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Sep 29, 2026 which is in 109 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on May 12, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 49,678,562 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went down -3.727%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.40 (162.14% Upside)
$5.40 (162.14% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $97.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.94%
12-Months-Change
Fundamentals
Return on Equity
-53.86%
Trailing 12-Months
Asset Growth
349.32%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.40
▲(162.14% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.61% Insiders
2.62% Mutual Funds
22.49% Other Institutional Investors
72.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---